BiotechTube

decitabine + azacitidine

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes

Trial Timeline

Nov 1, 2009 → —

NCT ID
NCT01011283

About decitabine + azacitidine

decitabine + azacitidine is a approved stage product being developed by Eisai for Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT01011283. Target conditions include Myelodysplastic Syndromes.

What happened to similar drugs?

6 of 18 similar drugs in Myelodysplastic Syndromes were approved

Approved (6) Terminated (6) Active (7)
✅DeferasiroxNovartisApproved
✅ICL670/DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅Epoetin betaRocheApproved
❌Placebo + Epoetin alfa + Placebo + Epoetin alfaJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01011283ApprovedTerminated

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Erlotinib HydrochlorideAstellas PharmaPhase 2
35
Decitabine + Decitabine + DecitabineEisaiPhase 2
35
Decitabine + Valproic AcidEisaiPhase 2
35
decitabine + decitabineEisaiPhase 2
35
DecitabineEisaiPhase 2
27
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
29
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
35
Subcutaneous DecitabineEisaiPhase 1
21
DecitabineEisaiPhase 2
35
Galunisertib + PlaceboEli LillyPhase 2/3
38
DSP-7888Sumitomo PharmaPhase 1/2
32
TP-0184Sumitomo PharmaPhase 1/2
24
DecitabineJohnson & JohnsonPhase 2
35
Epoetin alfaJohnson & JohnsonPhase 2
27
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
35
DecitabineJohnson & JohnsonPhase 2
27